Jade Biosciences, Inc. (JBIO) Stock Profile — Insider Trades & Financials

Net Income-$31.9M

EPS$-3.19

Market Cap$826.5M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Tom Frohlich

CEO & Executive Director

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The compnay also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Founded: 2024
Employees: 55
Headquarters: Waltham, Massachusetts, United States
Website

⚡

Core Efficiency

ROE?

-9.60%

ROA?

-9.13%

D/E Ratio?

0.05

📊

Profitability Ratios

Current Ratio?

21.09

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 19, 2026 (in 132 days)

Annual Report (10-K) — Based on filing pattern

Aug 19, 2026

Predicted10-K

Mar 6, 2026

10-KQ4 20256d after period end

Mar 6, 2026

10-KFY 202565d after period end

Nov 14, 2025

10-QQ3 20257d after period end

Aug 13, 2025

10-QQ2 20255d after period end

Apr 25, 2025

10-QQ1 20251d after period end

Mar 27, 2025

10-KQ4 20243d after period end

Mar 27, 2025

10-KFY 202486d after period end

Nov 12, 2024

10-QQ3 20244d after period end

Loading company sections...

Jade Biosciences, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness